Serum proteomics and ingenuity pathway analysis (IPA)-guided discovery of response markers to androgen ablation (AA) in prostate cancer.
Manish Kohli(Mayo Clinic in Arizona), Sheng Zhang(Tongji University), Douglas W. Mahoney, Deepak M. Sahasrabudhe(University of Rochester Medical Center), Rachel E. Carlson(Mayo Clinic in Florida), Roman M. Zenka(Mayo Clinic in Florida), Ann L. Oberg(University of Minnesota), Yuji Zhang, Rui Qin(Regeneron (United States)), Shaun M. Riska(Mayo Clinic in Florida)
Cited by 4
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma
|Annals of Surgery|2008|461